Mon, May 20, 2013, 8:32 AM EDT - U.S. Markets open in 58 mins.
Can anyone point me towards an article that breaks down the potential revenues from Vivitrol for this new market?
Never mind; I found it:from http://www.reuters.com/article/idCNN1317966020100914?rpc=44Sales could reach $125 million by 2015 if it wins the additional approval, said Steve Yoo, an analyst for Leerink Swann Research. Net sales from Vivitrol were $20.2 million for fiscal 2010, compared with $16.9 million for 2009 for Alkermes and its then-partner Cephalon Inc (CEPH.O), according to Alkermes.But it costs the company roughly $40 million to make and sell the drug, said Leerink's Yoo."Therefore, the opioid dependence indication is critical for commercial success," he added.